William Blair analyst Sami Corwin has maintained their bullish stance on CRSP stock, giving a Buy rating today.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sami Corwin has given his Buy rating due to a combination of factors related to Crispr Therapeutics AG’s innovative advancements and promising preclinical data. The company recently showcased its novel SyNTase gene-editing platform, which has demonstrated significant potential in treating alpha-1 antitrypsin deficiency (AATD) through its investigational candidate, CTX460. This platform utilizes engineered Cas9 nickases and polymerases to achieve precise genetic corrections, which are crucial for addressing the underlying mutations in AATD.
Furthermore, the preclinical results have been impressive, with CTX460 showing substantial liver DNA editing in in vivo models, indicating a high level of efficacy at low doses. The stability and efficiency of the SyNTase platform, combined with the potential for large-scale manufacturing, position Crispr Therapeutics AG as a strong contender in the gene-editing space. These factors collectively support Corwin’s optimistic outlook and Buy rating for the company’s stock.
Corwin covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Ultragenyx Pharmaceutical, and PTC Therapeutics. According to TipRanks, Corwin has an average return of 28.8% and a 58.82% success rate on recommended stocks.
In another report released today, Needham also maintained a Buy rating on the stock with a $81.00 price target.